Thesis 01 · Health & biology

Biomarker Expansion

A smartwatch reads about a dozen signals from the body. Science has cataloged tens of thousands of biomarkers and hundreds of thousands of metabolites. The next medical-grade markets will be created in that gap.

A flagship smartwatch today reads about a dozen signals: heart rate, heart-rate variability, ECG, blood oxygen, wrist temperature, respiratory rate, sleep stages, breathing disturbances, blood-pressure trends, cardio fitness, activity and ambient noise.1 Almost all of them are physical. They come from light, electricity and motion.

Chemistry is the frontier. As recently as 2022, a review of the field noted that the continuous glucose monitor and the pulse oximeter were the only commercially available sensors that measure molecules in the body at high frequency.2 Most of what the body says is chemical, and almost none of it is measured continuously.

01How much of the body do we actually measure?

Very little.

  • ~12 signals on a flagship wearable.1
  • 636 digital endpoints that industry sponsors have used in clinical trials, across 105 sponsors.3
  • 34,483 biomarkers cataloged in MarkerDB 2.0. Most are genetic, but 1,664 are chemical and 218 are proteins.4
  • 217,920 annotated metabolites in the Human Metabolome Database.5
  • Up to 5,400 proteins now being measured in each of 600,000 UK Biobank samples, the largest proteomics study ever attempted.6

For nearly all of these markers, we don't yet know how they move day to day, or how that movement relates to disease, longevity or performance. You can't learn that from an annual blood draw. You learn it from continuous measurement.

The measurement gap · biomarkers, log scale
Signals on a flagship wearable~12
Digital endpoints used in clinical trials636
Cataloged biomarkers (MarkerDB 2.0)34,483
Annotated human metabolites (HMDB 5.0)217,920

Each gridline is ten times more of the body. Consumer health lives in the first sliver.

02Why now?

Three curves are crossing.

1. Sensing is moving from physics to chemistry. Microneedle patches sample interstitial fluid just under the skin. In 2022, Joseph Wang's group at UC San Diego showed a wearable microneedle array that tracked glucose alongside lactate or alcohol in real time, matched against blood and breath references.7 In 2023, Wei Gao's group at Caltech built a wireless sweat patch that measures C-reactive protein, a core marker of inflammation, and tracked serum levels in patients with COPD, infections and heart failure.8 Electrochemical aptamer-based sensors bind a target without consuming it. In principle that makes them general to almost any molecule, including hormones and drugs at trace concentrations.2

2. Models learn physiology from raw signals. Dina Katabi's MIT lab trained a model on nocturnal breathing that detected Parkinson's disease with an AUC of 0.90 on held-out data and 0.85 on external cohorts. It worked on signals captured by a contactless radio device, with nothing worn on the body.9 Hand-built features would never have found that signal in breathing.

3. Regulators have paths for software that keeps learning. The FDA's final guidance on Predetermined Change Control Plans lets device makers specify planned model updates up front and roll them out without a new marketing submission for each one.10

03Where the first markets open

The first multi-analyte products are already here, and they show the pattern: one new chemical reading, one new buyer.

  • Glucose + ketones. In August 2026, the FDA authorized Abbott's Libre dual glucose-ketone sensor through De Novo, the first of its kind. It warns people on insulin of rising ketones before diabetic ketoacidosis sets in.11
  • Hydration and electrolytes. Gatorade's Gx Sweat Patch estimates sweat rate and sodium loss and turns them into hydration plans. It is a mass-market colorimetric patch, validated against lab methods.12
  • Next: the lab results above point toward inflammation (CRP), stress and endocrine markers (cortisol), and drug levels. Each is a new reading with a buyer waiting: a cardiology clinic, a pharma trial, an employer, an athlete.

04One signal, read differently

I saw this up close as the first go-to-market hire at Emerald Innovations, the MIT spin-out that brings Katabi's contactless radio sensing to clinical trials. Plenty of devices track breath rate. A model trained on how someone breathes turned an ordinary signal into evidence of Parkinson's,9 and opened buyers in pharma trials and care facilities that a breath counter could never reach. That was one existing biomarker, read differently. The catalog above holds tens of thousands more.

What I look for

  • Modality: does it measure something no consumer device measures today, or read an existing signal in a way that reveals something new?
  • Flywheel: does every trial, partner or user make the model better in a way a competitor can't buy?
  • Validation: is there a credible path from a lab reference standard to clinical evidence and a regulatory pathway?
  • Buyer: does the team understand who pays as deeply as they understand the science?

What would make me wrong?

  • Biology fights the sensor. Proteins and debris foul electrodes over days of wear, and readings drift.2
  • Sweat and interstitial fluid aren't blood. Small molecules like glucose track blood closely. For larger proteins, correlation varies by person and needs rigorous clinical validation.13
  • Power and form factor. Continuous, multi-channel chemistry needs more power and space than a ring or a watch has to give today.
  • Timelines outlast venture timelines. Validation and reimbursement can take longer than a fund can wait.
  • Incumbents move first. Abbott shipped dual-analyte sensing on its existing CGM distribution.11 Large device makers can fold in new sensors faster than startups can build distribution.

Qualifications

ISignal

Is the measurement real, new and capturable?

  1. 1.What are you measuring, or how are you measuring it, that no consumer device does today?

    A new way to capture a familiar signal counts. Reading breathing by radio, with nothing worn, means it can be captured every night instead of once in a sleep lab. Every extra hour of capture fills in more of the picture.

  2. 2.How was the signal validated, against what reference, in how many people?

    Small, homogeneous cohorts are where most digital biomarkers quietly fail.

  3. 3.What does it take to capture it every day, and how does that shape how you go to market?

    Adherence decides whether a biomarker becomes a dataset. The form factor (patch, ring, bedside device) decides who buys it and how it reaches them.

IIData

Does the data compound?

  1. 4.How does each new user, trial or partner make the model better?

    The strongest companies bootstrap proprietary data through partners who pay for the privilege.

  2. 5.Who owns the data, and what consent covers future uses?

    The most valuable use of a dataset is usually one nobody planned for.

  3. 6.How deep is the longitudinal record: days, months or years?

    Progression and prediction need time series, not snapshots.

IIIApplication

What's the path to medical grade?

  1. 7.Which regulatory path are you on, and what's the timeline?

    Wellness, 510(k) and De Novo are different companies with different burn.

  2. 8.What clinical evidence exists today, and what still needs to be proven?

    New studies should open new applications or new buyers.

IVBuyer

Who pays, and why now?

  1. 9.Who signs the first contract, and what is the quantified value proposition?

    Consumers, employers, payers, providers and pharma each buy on a different number. I want to see that number, and how it grows as the evidence does.

  2. 10.What does pilot-to-contract look like, and how long does it take?

    This is the real development cycle. How do you source pilots, how do they become contracts, and how does each relationship open the next one?

  3. 11.What locks the revenue in, and what puts it at risk?

    Reimbursement codes, workflow integration and data switching costs hold customers. A single payer, a policy change or an incumbent bundling the feature for free can take them away.

If you're building at this edge, I want to hear from you.

Tell me what you're measuring and who it's for. I read every submission myself and connect the strongest founders with the investors and operators who should know them.

Next: Thesis 02 · Inverse Design for Matter →
Raising now?

140 characters max

Sources

  1. 1.Apple, “Apple debuts Apple Watch Series 11 featuring groundbreaking health insights,” Sept 2025. apple.com
  2. 2.Downs & Plaxco, “Real-Time, In Vivo Molecular Monitoring Using Electrochemical Aptamer Based Sensors: Opportunities and Challenges,” ACS Sensors, 2022. pmc.ncbi.nlm.nih.gov
  3. 3.Digital Medicine Society (DiMe), Library of Digital Endpoints, updated April 2026. dimesociety.org
  4. 4.MarkerDB 2.0 statistics. markerdb.ca
  5. 5.Wishart et al., “HMDB 5.0: the Human Metabolome Database for 2022,” Nucleic Acids Research, 2022. pmc.ncbi.nlm.nih.gov
  6. 6.UK Biobank, “Launch of world’s most significant protein study,” 2025. ukbiobank.ac.uk
  7. 7.Tehrani, Teymourian et al., “An integrated wearable microneedle array for the continuous monitoring of multiple biomarkers in interstitial fluid,” Nature Biomedical Engineering, 2022. pubmed.ncbi.nlm.nih.gov
  8. 8.Tu, Min, Song et al., “A wireless patch for the monitoring of C-reactive protein in sweat,” Nature Biomedical Engineering, 2023. nature.com
  9. 9.Yang, Yuan et al., “Artificial intelligence-enabled detection and assessment of Parkinson’s disease using nocturnal breathing signals,” Nature Medicine, 2022. nature.com
  10. 10.FDA, “Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions,” final guidance. fda.gov
  11. 11.Abbott, “Abbott receives FDA authorization for world’s first dual glucose-ketone sensing technology,” Aug 2026. abbott.mediaroom.com
  12. 12.Gatorade Sports Science Institute, “Gx Sweat Patch and App for Personalized Hydration.” gssiweb.org
  13. 13.Ibrahim et al., “A Comprehensive Review of the Recent Developments in Wearable Sweat-Sensing Devices,” Sensors, 2022. pmc.ncbi.nlm.nih.gov